ETFS S&P Biotech ETF (CURE) - Research

$51.600 0.04 (0.08%)

CURE General Information +

ASX Code CURE
Website http://www.etfsecurities.com.au
GICS Sub-Industry --
Market Cap ($M) 1
Current Price $51.600
Day High $51.770
Day Low $51.600
Last Close $51.640
Price Movement $0.04 ( 0.08% )
Prices as at 16:40, 17 Jul 2019
+Security prices are delayed by at least 20 minutes and are indicative only.

CURE Company Overview

Business Description

ETFS S&P Biotech ETF (CURE) provides exposure to the US biotechnology sub-industry within the health care sector. The fund adopts an equally weighted strategy which gives higher exposure to small and mid-cap stocks held within the fund compared to market capitalization weighted approach.

CURE Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
ETFS S&P Biotech ETF (CURE) $5M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

CURE Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.00 0.00
Market 0.66 14.70 1.17 1.01
Sector 0.00 0.00 0.00 0.00

CURE Directors

Name Position Start Date
Mr Kris Walesby Chief Executive Officer, Executive Director 1 Jan 0001
Mr Graham Tuckwell Non-Executive Chairman, Non-Executive Director 1 Jan 0001
Dr Vincent William J Fitzgerald Non-Executive Director 1 Jan 0001

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.